MET and non-small cell lung carcinoma: While we are expecting conclusive data from the clinical trials currently investigating new MET inhibitors in the setting of acquired resistance to EGFR-TKIs in [11,12,67,96], EGFRm+ NSCLC patients with both de novo and acquired MET amplification, who cannot be included in these trials, may be offered a combination of EGFR-TKI and Crizotinib, which is a feasible and reasonable approach.